Pre-Submission Review for Hematology Papers

Hematology reviewers often ask:

• is the disease entity defined precisely?
• are treatment line, risk category, molecular subtype, and prior therapy clear?
• are response, progression, survival, minimal residual disease, thrombosis, bleeding, transfusion, or laboratory endpoints mature enough?
• is safety reported in enough detail?
• does the translational mechanism explain the clinical or biological finding?
• are subgroup claims powered and biologically plausible?
• is the correct reporting checklist included?
• does the manuscript fit Blood, Blood Advances, Haematologica, Journal of Hematology & Oncology, a thrombosis journal, or a specialty venue?

The manuscript has to show that the hematology details are not interchangeable with generic clinical medicine.

In our pre-submission review work, hematology manuscripts most often fail when the evidence is promising but the endpoint or phenotype story is too loose for the target journal.

Phenotype blur: disease classification, molecular subgroup, risk stratum, treatment line, or prior therapy is not defined precisely enough.

Endpoint immaturity: response or biomarker changes are emphasized before follow-up, survival, durability, safety, or clinical consequence is mature enough.

Safety underreporting: cytopenias, infection, bleeding, thrombosis, immune toxicity, transfusion burden, or treatment discontinuation are not described at the level reviewers expect.

Translational gap: mechanism figures are included, but they do not explain patient selection, response, resistance, or disease biology.

Journal mismatch: the manuscript is aimed at Blood when the evidence package is better suited to Blood Advances, Haematologica, JHO, or a disease-specific journal.

A useful review should identify the first hematology-specific objection.

Blood Advances submission materials say ASH membership is not required for submission or publication and explain the manuscript submission process. Haematologica author guidance says basic studies on hematopoiesis, blood cells, hemostasis, and blood banking are considered when they have potential clinical relevance, which is an important scope signal for translational hematology papers.

Blood & Plasma guidance recommends ICMJE practice, appropriate reporting guidelines, completed checklists, author contribution statements, and declarations. The broader reporting ecosystem for clinical trials, observational studies, reviews, diagnostic accuracy, and case reports still matters through EQUATOR guidance.

Those signals make hematology readiness a combination of disease specificity, reporting discipline, and journal-lane fit.

Send the manuscript, target journal, protocol, reporting checklist, endpoint definitions, disease classification criteria, treatment-line details, molecular or cytogenetic data, safety tables, follow-up maturity, statistical analysis plan, figures, supplement, data statement, and prior reviewer comments if available.

If the paper involves a trial, include registration, protocol, CONSORT materials, and adverse-event reporting. If it is translational, include the bridge between model, biomarker, or assay and the hematology claim.

A useful hematology pre-submission review should include:

• hematology-claim verdict
• phenotype and endpoint critique
• safety and follow-up review
• translational-mechanism check
• statistics and subgroup review
• reporting-guideline check
• journal-lane recommendation
• submit, revise, retarget, or diagnose deeper call

The review should not only say "add clinical relevance." It should identify which hematology detail changes the editorial decision.

Before submission, authors often need to:

• sharpen disease and risk definitions
• clarify treatment line and prior therapy
• separate exploratory biomarker claims from clinical conclusions
• add safety, durability, or follow-up context
• temper subgroup language
• improve translational figure logic
• complete trial, observational, diagnostic, review, or case-report checklists
• retarget from Blood to Blood Advances, Haematologica, JHO, thrombosis, transfusion, or disease-specific journals

These fixes prevent a hematology paper from sounding broader or more mature than the evidence allows.

A malignant hematology trial needs eligibility, disease subtype, treatment line, response criteria, durability, survival, safety, and MRD context where relevant. A benign hematology paper needs phenotype clarity, clinical consequence, and management relevance. A thrombosis paper needs event definitions, anticoagulation context, bleeding risk, and competing outcomes. A transfusion paper needs product, indication, safety, and operational context. A translational paper needs mechanism tied to disease biology or clinical relevance, not only a pathway result.

The AI manuscript review can flag whether the blocking risk is phenotype, endpoint maturity, safety, translational logic, or journal fit.

Use this page when the manuscript's submission risk depends on hematology-specific disease definitions, endpoints, safety, translational blood biology, thrombosis, transfusion, or hematology journal targeting. Use broad medical review when the paper is a general clinical manuscript where hematology is incidental rather than central.

That distinction keeps the page focused on the hematology buyer's actual problem.

Do not submit a hematology paper if the cohort definition or endpoint maturity is still unstable. Reviewers can forgive limitations, but they need to know exactly which patients, disease states, endpoints, and follow-up window the manuscript is claiming.

Also pause if the paper's strongest claim is a subgroup result without enough power, biological rationale, or replication. In hematology, subgroup findings can be clinically tempting, but they are easy for reviewers to downgrade if the design cannot support them.

For cellular therapy, transplant, or immunotherapy papers, pause again if toxicity and sequencing context are thin. Response alone rarely tells the whole story. Reviewers need to understand eligibility, bridging treatment, prior therapy, immune effects, infections, cytopenias, relapse patterns, and follow-up before they can judge whether the result is clinically meaningful.